{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:37:24Z","timestamp":1791488244350,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"crossref","award":["P3-0083"],"award-info":[{"award-number":["P3-0083"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hepatitis C virus (HCV) infection remains a public health threat. Although therapy with direct-acting antivirals made its elimination possible, major challenges remain in treating vulnerable populations, such as people who inject drugs (PWID) enrolled in low-threshold programmes (LTPs). This study analysed the outcome of HCV management focused on HCV reinfection in a specifically designed model-of-care (MoC) for PWID in Slovenia, where treatment is prescribed without limitations, though only by specialist physicians.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>All HCV antibody (anti-HCV) positive users of a MoC, combining HCV management at Clinic for Infectious Diseases at the University Medical Centre in Ljubljana and LTP for PWID in 100\u00a0km distanced civil society organisation (CSO) Svit Koper, between January 2017 to December 2022, were included. The MoC enabled regular transportation of PWID between LTP and the Clinic, where specifically assigned services for individually tailored HCV management in cooperation with CSO were available. Data on participants\u00b4 demographic, epidemiological, and clinical characteristics were collected partly retrospectively and prospectively, with a particular focus on HCV treatment outcome and reinfection status, and analysed accordingly.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study included 49 anti-HCV positive PWID with a mean age of 38.7 (standard deviation (SD)\u2009=\u20097.6) years at first visit. The majority was male (40\/49, 81.6%); 16\/49 (32.7%) experienced previous incarceration, 14\/49 (28.6%) were experiencing homelessness, and 42\/49 (85.7%) were receiving opioid agonist therapy. A total of 42\/49 (83.7%) were HCV RNA-positive. Of them 36\/42 (85.7%) started HCV treatment at a mean age of 42.7 (SD\u2009=\u20095.7) years and 33\/36 (91.7%) completed treatment. Six (14.3%) HCV RNA-positive PWID died. Among 28\/33 (84.9%) who achieved a sustained virological response 12 weeks post treatment, 6\/28 (21.4%) presented with reinfection. The HCV reinfection rate was 13.3 per 100 \u2013 PY (95% confidence interval (CI) [6.0, 29.7]), the rate of positive HCV RNA re-test was 12.2 per 100 \u2013 PY (95%CI [7.7\u201316.7]), while hazard of reinfection in our cohort increased with time, with the estimated reinfection probability exceeding 0.5 at 4 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In marginalised population of PWID attending LTP, a sustainable HCV RNA re-screening and follow-up after HCV cure are necessary, as the risk of reinfection remains high.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12954-025-01164-5","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T08:54:57Z","timestamp":1739436897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Addressing viral hepatitis C reinfections in a low-threshold programme for people who inject drugs in Slovenia"],"prefix":"10.1186","volume":"22","author":[{"given":"Jasna","family":"\u010cerno\u0161a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelka Megli\u010d","family":"Volkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Poljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja Pohar","family":"Perme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Victor","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Mati\u010di\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"1164_CR1","volume-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva, Switzerland: World Health Organization; 2024."},{"issue":"1","key":"1164_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/liv.13949","volume":"39","author":"E Day","year":"2019","unstructured":"Day E, Hellard M, Treloar C, Bruneau J, Martin NK, \u00d8vrehus A, et al. Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int. 2019;39(1):20\u201330.","journal-title":"Liver Int"},{"issue":"3","key":"1164_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0038-1666841","volume":"38","author":"JV Lazarus","year":"2018","unstructured":"Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. The micro-elimination approach to eliminating hepatitis C: Strategic and operational considerations. Semin Liver Dis. 2018;38(3):181\u201392.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"1164_CR4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1186\/s12889-023-16017-8","volume":"23","author":"CR Balsom","year":"2023","unstructured":"Balsom CR, Farrell A, Kelly DV. Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - a scoping review of the qualitative evidence. BMC Public Health. 2023;23(1):1038.","journal-title":"BMC Public Health"},{"issue":"1","key":"1164_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12954-020-00439-3","volume":"17","author":"M Maticic","year":"2020","unstructured":"Maticic M, Pirnat Z, Leicht A, Zimmermann R, Windelinck T, Jauffret-Roustide M, et al. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct J. 2020;17(1):89.","journal-title":"Harm Reduct J"},{"issue":"3","key":"1164_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/jvh.12859","volume":"25","author":"O Falade-Nwulia","year":"2018","unstructured":"Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25(3):220\u20137.","journal-title":"J Viral Hepat"},{"issue":"10","key":"1164_CR7","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/cid\/ciac272","volume":"75","author":"JM Johannesson","year":"2022","unstructured":"Johannesson JM, Fridriksdottir RH, L\u00f6ve TJ, Runarsdottir V, Hansd\u00f3ttir I, L\u00f6ve A, et al. Treatment as Prevention for Hepatitis C (TraP hep C) group. High rate of Hepatitis C Virus Reinfection among recently injecting drug users: results from the TraP hep C Program-A prospective Nationwide, Population-based study. Clin Infect Dis. 2022;75(10):1732\u201339.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1164_CR8","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1111\/jvh.13614","volume":"28","author":"M Caven","year":"2021","unstructured":"Caven M, Baiano CX, Robinson EM, Stephens B, Macpherson I, Dillon JF. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland. J Viral Hepat. 2021;28(12):1744\u201350.","journal-title":"J Viral Hepat"},{"issue":"5","key":"1164_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/joim.12972","volume":"286","author":"JV Lazarus","year":"2019","unstructured":"Lazarus JV, Peric\u00e0s JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med. 2019;286(5):503\u201325.","journal-title":"J Intern Med"},{"issue":"10319","key":"1164_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, et al. The EASL-Lancet Liver Commission: protecting the next generation of europeans against liver disease complications and premature mortality. Lancet. 2022;399(10319):61\u2013116.","journal-title":"Lancet"},{"key":"1164_CR11","doi-asserted-by":"publisher","first-page":"100792","DOI":"10.1016\/j.lanepe.2023.100792","volume":"36","author":"C Thomadakis","year":"2023","unstructured":"Thomadakis C, Gountas I, Duffell E, Gountas K, Bluemel B, Seyler T, et al. Prevalence of chronic HCV infection in EU\/EEA countries in 2019 using multiparameter evidence synthesis. Lancet Reg Health Eur. 2023;36:100792.","journal-title":"Lancet Reg Health Eur"},{"key":"1164_CR12","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1016\/S0168-8278(18)30599-3","volume":"68","author":"M Maticic","year":"2018","unstructured":"Maticic M, Lekse A, Kozinc M, Benedik Dolnicar M, Andoljsek D, Preloznik Zupan I, et al. Micro-elimination of hepatitis C among patients with congenital bleeding disorders in Slovenia. J Hepatol. 2018;68:S193\u20134.","journal-title":"J Hepatol"},{"key":"1164_CR13","unstructured":"Nacionalni in\u0161titut za javno zdravje. Letno poro\u010dilo za leto 2021. https:\/\/nijz.si\/wp-content\/uploads\/2022\/12\/letno_porocilo_nijz_2021_koncno.pdf. Accessed 21st January 2024."},{"issue":"6","key":"1164_CR14","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/1471-2334-14-S6-S6","volume":"14","author":"M Maticic","year":"2014","unstructured":"Maticic M. A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia. BMC Infect Dis. 2014;14(6):S6.","journal-title":"BMC Infect Dis"},{"key":"1164_CR15","volume-title":"European drug report 2022: trends and developments","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2022","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2022: trends and developments. Luxembourg: Publications Office of the European Union; 2022."},{"key":"1164_CR16","unstructured":"Alliance of Non-Governmental Organisations for Drugs and Addictions. https:\/\/www.zmanjsevanje-skode.si. Accessed 21 January 2025."},{"key":"1164_CR17","unstructured":"Cernosa J, Meglic Volkar J, Videcnik J, Vidmar Vovko D, Pirnat Z, Gregorcic S et al. A model of care to micro-eliminate hepatitis C in PWID managed at a low-threshold program in Slovenia. Poster presented at: The 11th International Conference on Health and Hepatitis in Substance Users; 2023 Oct 17\u201320; Geneva, Switzerland. Abstract number 328."},{"key":"1164_CR18","unstructured":"Association for support to individuals with addiction and their families Svit Koper. https:\/\/www.svit-kp.org. Accessed 21 January 2024."},{"key":"1164_CR19","doi-asserted-by":"crossref","unstructured":"Bogaerts K, Komarek A, Lesaffre E. Survival analysis with interval-censored data: a practical approach with examples in R, SAS, and BUGS. 1st ed. Chapman and Hall\/CRC; 2017.","DOI":"10.1201\/9781315116945"},{"key":"1164_CR20","volume-title":"R: a language and environment for statistical computing. R Foundation for Statistical Computing","author":"R Core Team","year":"2024","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2024."},{"key":"1164_CR21","unstructured":"Maticic M, Cernosa J, Bajec B, Zelnikar B, Zamernik E, Korenjk M et al. Prevalence and characteristics of HCV infection in people who use drugs managed low threshold settings in Slovenia: results from a national study. Poster presented at: The 7th International Conference on Health and Hepatitis in Substance Users; 2018 Sep 19\u201331; Cascais, Portugal. Abstract number 50."},{"key":"1164_CR22","unstructured":"Cernosa J, Korenjak M, Bajec B, Zelnikar B, Zamernik E, Poljak M et al. Stage of liver fibrosis in people who inject drugs managed at low-threshold settings in Slovenia: results of a national study. Poster presented at: The 8th International Conference on Health and Hepatitis in Substance Users; 2018 Sep 11\u201313; Montreal, Canada. Abstract number 043."},{"issue":"1","key":"1164_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1186\/s12913-019-4635-7","volume":"19","author":"A Radley","year":"2019","unstructured":"Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, Dillon JF. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Serv Res. 2019;19(1):765.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"1164_CR24","doi-asserted-by":"publisher","first-page":"e1003653","DOI":"10.1371\/journal.pmed.1003653","volume":"18","author":"LT Fadnes","year":"2021","unstructured":"Fadnes LT, Aas CF, Vold JH, Leiva RA, Ohldieck C, Chalabianloo F, INTRO-HCV Study Group, et al. Integrated treatment of hepatitis C virus infection among people who inject drugs: a multicenter randomized controlled trial (INTRO-HCV). PLoS Med. 2021;18(6):e1003653.","journal-title":"PLoS Med"},{"issue":"7","key":"1164_CR25","doi-asserted-by":"publisher","first-page":"ofac225","DOI":"10.1093\/ofid\/ofac225","volume":"9","author":"B Eckhardt","year":"2022","unstructured":"Eckhardt B, Kapadia SN, Mateu-Gelabert P, Pai M, Fong C, Aponte-Melendez Y, Marks KM. Rapid Treatment Initiation for Hepatitis C in Young people who inject drugs: the seek, test, and Rapid Treatment Randomized Trial. Open Forum Infect Dis. 2022;9(7):ofac225.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"1164_CR26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1001\/jamainternmed.2022.0170","volume":"182","author":"B Eckhardt","year":"2022","unstructured":"Eckhardt B, Mateu-Gelabert P, Aponte-Melendez Y, Fong C, Kapadia S, Smith M, Edlin BR, Marks KM. Accessible Hepatitis C Care for people who inject drugs: a Randomized Clinical Trial. JAMA Intern Med. 2022;182(5):494\u2013502.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"1164_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"issue":"5","key":"1164_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"issue":"1","key":"1164_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12954-023-00801-1","volume":"20","author":"K Lindqvist","year":"2023","unstructured":"Lindqvist K, Thorin Z, K\u00e5berg M. Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden. Harm Reduct J. 2023;20(1):72.","journal-title":"Harm Reduct J"},{"key":"1164_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.drugpo.2019.06.016","volume":"72","author":"J Valencia","year":"2019","unstructured":"Valencia J, Alvaro-Meca A, Troya J, Cuevas G, Guti\u00e9rrez J, Morro A, et al. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy. 2019;72:181\u201388.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1164_CR31","doi-asserted-by":"publisher","first-page":"100319","DOI":"10.1016\/j.jve.2023.100319","volume":"9","author":"M Schwarz","year":"2023","unstructured":"Schwarz M, Schwarz C, Sch\u00fctz A, Schwanke C, Krabb E, Schubert R, et al. Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy. J Virus Erad. 2023;9(1):100319.","journal-title":"J Virus Erad"},{"key":"1164_CR32","doi-asserted-by":"publisher","first-page":"103165","DOI":"10.1016\/j.drugpo.2021.103165","volume":"96","author":"H Midgard","year":"2021","unstructured":"Midgard H, Ulstein K, Backe \u00d8, Foshaug T, S\u00f8rli H, Vennesland K, et al. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway. Int J Drug Policy. 2021;96:103165.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1164_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","volume":"2","author":"N Islam","year":"2017","unstructured":"Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, et al. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. Lancet Gastroenterol Hepatol. 2017;2(3):200\u201310.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"1164_CR34","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","volume":"69","author":"C Rossi","year":"2018","unstructured":"Rossi C, Butt ZA, Wong S, Buxton JA, Islam N, Yu A, et al. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. J Hepatol. 2018;69(5):1007\u201314.","journal-title":"J Hepatol"},{"issue":"12","key":"1164_CR35","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1111\/liv.14152","volume":"39","author":"NH Latham","year":"2019","unstructured":"Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, et al. Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs. Liver Int. 2019;39(12):2244\u201360.","journal-title":"Liver Int"},{"issue":"4","key":"1164_CR36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","volume":"72","author":"B Hajarizadeh","year":"2020","unstructured":"Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. J Hepatol. 2020;72(4):643\u201357.","journal-title":"J Hepatol"},{"issue":"8","key":"1164_CR37","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/jvh.13835","volume":"30","author":"M Hibbert","year":"2023","unstructured":"Hibbert M, Simmons R, Harris H, Desai M, Sabin CA, Mandal S. Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England. J Viral Hepat. 2023;30(8):646\u201355.","journal-title":"J Viral Hepat"},{"issue":"5","key":"1164_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/jvh.13035","volume":"26","author":"J Schulkind","year":"2019","unstructured":"Schulkind J, Stephens B, Ahmad F, Johnston L, Hutchinson S, Thain D, et al. High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. J Viral Hepat. 2019;26(5):519\u201328.","journal-title":"J Viral Hepat"},{"issue":"3","key":"1164_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2021.09.038","volume":"76","author":"A Yeung","year":"2022","unstructured":"Yeung A, Palmateer NE, Dillon JF, McDonald SA, Smith S, Barclay S, et al. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. J Hepatol. 2022;76(3):549\u201357.","journal-title":"J Hepatol"},{"issue":"8","key":"1164_CR40","doi-asserted-by":"publisher","first-page":"e2430024","DOI":"10.1001\/jamanetworkopen.2024.30024","volume":"7","author":"AH Litwin","year":"2024","unstructured":"Litwin AH, Tsui JI, Heo M, et al. Hepatitis C Virus Reinfection among people who inject drugs: long-term Follow-Up of the HERO study. JAMA Netw Open. 2024;7(8):e2430024.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"1164_CR41","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/cid\/ciaa253","volume":"72","author":"EB Cunningham","year":"2021","unstructured":"Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, et al. Reinfection following successful direct-acting antiviral therapy for Hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2021;72(8):1392\u2013400.","journal-title":"Clin Infect Dis"},{"key":"1164_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.drugpo.2019.05.024","volume":"72","author":"J Holeksa","year":"2019","unstructured":"Holeksa J, Magel T, Alimohammadi A, Thiam A, Yung R, Chu L, et al. Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada. Int J Drug Policy. 2019;72:177\u201380.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1164_CR43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/00365521.2019.1580764","volume":"54","author":"M K\u00e5berg","year":"2019","unstructured":"K\u00e5berg M, Edgren E, Hammarberg A, Weiland O. Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange - evaluated with liver elasticity. Scand J Gastroenterol. 2019;54(3):319\u201327.","journal-title":"Scand J Gastroenterol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01164-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T08:55:03Z","timestamp":1739436903000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01164-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1164"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01164-5","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Slovenian National Medical Ethics Committee (number 0120\u2013622\/2020\/11).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jeffrey Victor Lazarus acknowledges support to ISGlobal from grant CEX2023-0001290-S, funded by MCIN\/AEI\/10.13039\/501100011033, and the \u00b4Generalitat de Catalunya\u00b4, through the CERCA programme, outside of the submitted work. Jeffrey Victor Lazarus acknowledges grants to ISGlobal from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal, MSD, Novo Nordisk, Pfizer, and Roche Diagnostics, consulting fees from Echosens, NovoVax, GSK, Novo Nordisk, and Pfizer, and payment or honoraria for lectures from AbbVie, Echosens, Gilead Sciences, Janssen, Moderna, MSD, Novo Nordisk, and Pfizer, outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}